Abbott Laboratories (NYSE:ABT) Shares Bought by Syntegra Private Wealth Group LLC

Syntegra Private Wealth Group LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,693 shares of the healthcare product maker’s stock after purchasing an additional 118 shares during the period. Syntegra Private Wealth Group LLC’s holdings in Abbott Laboratories were worth $1,397,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Moneta Group Investment Advisors LLC grew its stake in Abbott Laboratories by 104,649.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 30,247,436 shares of the healthcare product maker’s stock worth $3,320,866,000 after acquiring an additional 30,218,560 shares during the period. Norges Bank purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $1,893,715,000. Morgan Stanley grew its stake in Abbott Laboratories by 14.3% in the 4th quarter. Morgan Stanley now owns 38,966,499 shares of the healthcare product maker’s stock worth $4,278,132,000 after acquiring an additional 4,886,954 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in Abbott Laboratories by 83.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 4,925,012 shares of the healthcare product maker’s stock worth $582,924,000 after acquiring an additional 2,235,314 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Abbott Laboratories by 99.8% in the 1st quarter. Renaissance Technologies LLC now owns 3,140,866 shares of the healthcare product maker’s stock worth $371,753,000 after acquiring an additional 1,568,700 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on ABT. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $116.00 to $121.00 and gave the company an “overweight” rating in a research note on Wednesday, December 13th. Barclays boosted their price objective on shares of Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research note on Friday, January 26th. Citigroup boosted their price objective on shares of Abbott Laboratories from $123.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $128.00 price target on shares of Abbott Laboratories in a research report on Wednesday, February 14th. Finally, TheStreet raised shares of Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $120.00.

Insiders Place Their Bets

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 12,500 shares of the company’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $120.00, for a total value of $1,500,000.00. Following the completion of the transaction, the executive vice president now owns 78,704 shares in the company, valued at approximately $9,444,480. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, EVP Andrea F. Wainer sold 42,500 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the transaction, the executive vice president now directly owns 65,027 shares in the company, valued at $7,315,537.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrea F. Wainer sold 12,500 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the executive vice president now owns 78,704 shares of the company’s stock, valued at $9,444,480. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,435 shares of company stock worth $6,451,298. Insiders own 1.10% of the company’s stock.

Abbott Laboratories Stock Up 0.1 %

ABT stock traded up $0.16 during trading on Thursday, reaching $113.64. The stock had a trading volume of 5,278,016 shares, compared to its average volume of 5,747,185. The company has a market capitalization of $197.19 billion, a P/E ratio of 34.94, a PEG ratio of 2.68 and a beta of 0.75. The firm has a fifty day moving average price of $115.13 and a 200 day moving average price of $106.42. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.19. Abbott Laboratories had a net margin of 14.27% and a return on equity of 20.65%. The business had revenue of $10.24 billion during the quarter, compared to the consensus estimate of $10.19 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. On average, equities analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 1.94%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.48%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.